Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Chem Biol Drug Des. 2013 Nov;82(5):595-602. doi: 10.1111/cbdd.12189. Epub 2013 Aug 21.
Owing to its special role as a negative regulator in both insulin and leptin signaling, protein tyrosine phosphatase-1B (PTP1B) has drawn considerable attention as a target for treating type 2 diabetes and obesity. It, however, is a great challenge to discover inhibitors specific to each PTP due to the highly homologous. In this study, a series of compounds were discovered to inhibit PTP1B based on imidazolidine-2,4-dione by means of 'core hopping'. A selective PTP1B inhibitor (comp#h) was identified, and molecular dynamics simulation and binding free energy calculation were carried out to propose the most likely binding mode of comp#h with PTP1B. The findings reported here may provide a new strategy in discovering selective and effective inhibitors for treating diabetes.
由于其在胰岛素和瘦素信号中作为负调节剂的特殊作用,蛋白酪氨酸磷酸酶-1B(PTP1B)作为治疗 2 型糖尿病和肥胖症的靶点引起了相当大的关注。然而,由于高度同源性,发现针对每种 PTP 的抑制剂是一项巨大的挑战。在这项研究中,通过“核心跳跃”发现了一系列基于咪唑烷-2,4-二酮的化合物来抑制 PTP1B。鉴定出一种选择性 PTP1B 抑制剂(化合物 #h),并进行了分子动力学模拟和结合自由能计算,以提出化合物 #h 与 PTP1B 最可能的结合模式。这里报道的研究结果可能为发现治疗糖尿病的选择性和有效抑制剂提供新策略。